Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104631 | 0.80 | MAOB (0.37) | HDAC1HDAC8KDM4ENPC1RAB9A | |
| SCHEMBL23677943 | 0.79 | HDAC1 (0.35) | HDAC1HDAC8KDM4ELMNA | |
| SCHEMBL13749316 | 0.75 | GRM5 (0.42) | HDAC1HDAC8 | |
| SCHEMBL14294456 | 0.73 | NPC1 (0.43) | KDM4ENPC1LMNAGAAHPGD | |
| SCHEMBL7916582 | 0.70 | HRH4 (0.38) | KDM4ENPC1LMNAGAAHPGD | |
| SCHEMBL6125859 | 0.68 | DYRK1A (0.37) | GAAHSD17B10 | |
| SCHEMBL1104630 | 0.68 | MET (0.46) | HDAC1HDAC8HTTSMN1; SMN2HSD17B10 | |
| SCHEMBL31221748 | 0.68 | MET (0.46) | HDAC1HDAC8HTTSMN1; SMN2HSD17B10 | |
| SCHEMBL13749777 | 0.68 | CHRNB2 (0.31) | — | |
| SCHEMBL14268920 | 0.66 | MAPT (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209547-A1 | C-8 HALOGENATED MACROLIDES | CYP2C8, CCR8, CXCL8 | HDAC1 423/4885HDAC8 16/4885KDM4E 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.